Arab Finance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 26.88% year-on-year (YoY) increase in consolidated profits attributable to the parent company during the first nine months of 2026, according to the financial statements filed to the Egyptian Exchange (EGX) on November 11.
The company’s consolidated profits excluding minority interest surged to EGP 340.404 million in the nine months to September 30 from EGP 268.291 million in the same period a year earlier.
Revenue jumped to EGP 3.270 billion in January-September from EGP 2.963 billion in the year-ago period.
Furthermore, standalone net profit after tax declined to EGP 328.004 million in the period from January 1 to September 30 from EGP 273.068 million in the same period last year.
Ramada is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals. It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.
